| 1245813-10-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• CAS: 1245813-10-8
• 化学式: C₂₆H₂₉N₄O₄P
• 分子量: 492.514
• InChiKey: KPJKBUDXBSKPAJ-KESTWPANSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  35.0
• 可旋转键数：
  5.0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  119.92
• 氢给体数：
  2.0
• 氢受体数：
  7.0

文献信息

• Inhibitors of diacylglycerol o-acyltransferase 1 (DGAT-1) and uses thereof
  申请人：Metabasis Therapeutics, Inc.

  公开号：EP2805951A2

  公开（公告）日：2014-11-26

  The invention pertains to use of DGAT-1 inhibitors to treat and/or prevent overweight, obesity and various diseases and disorders associated therewith. Other conditions also can be ameliorated or avoided, such as high postprandial triglycerides or diet-related hypertriglyceridemia, cardiovascular risk associated with excessive triglycerides, and insulin resistance/glucose intolerance in overweight patients, those with diabetes or other glucose metabolic disorders such as Syndrome X and/or polycystic ovary disease. Compounds and compositions suitable for use in the disclosed methods are also provided.

  本发明涉及使用 DGAT-1 抑制剂治疗和/或预防超重、肥胖以及与之相关的各种疾病和失调。还可改善或避免其他病症，如餐后甘油三酯过高或与饮食相关的高甘油三酯血症、与甘油三酯过高相关的心血管风险，以及超重患者、糖尿病患者或其他糖代谢紊乱（如 X 综合征和/或多囊卵巢疾病）患者的胰岛素抵抗/葡萄糖不耐受。还提供了适用于所公开方法的化合物和组合物。
• Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof
  申请人：METABASIS THERAPEUTICS, INC.

  公开号：US10034891B2

  公开（公告）日：2018-07-31

  The invention pertains to the use of compounds represented by the formula, Q-G1-G2-G3-G4-Z, where Q is The compounds can be used as diacylglycerol O-acyltransferase 1 (DGAT-1) inhibitors to treat hyperlipidiemias and various diseases and disorders associated therewith. Other conditions also can be ameliorated or avoided, such as high postprandial triglycerides or diet-related hypertriglyceridemia, cardiovascular risk associated with excessive triglycerides, and insulin resistance/glucose intolerance in overweight patients, those with diabetes or other glucose metabolic disorders such as Syndrome X and/or polycystic ovary disease.

  本发明涉及由式 Q-G1-G2-G3-G4-Z 所代表的化合物的用途，其中 Q 是 该化合物可用作二酰甘油 O-酰基转移酶 1（DGAT-1）抑制剂，以治疗高脂血症及与之相关的各种疾病和失调。 还可改善或避免其他病症，如餐后甘油三酯过高或与饮食相关的高甘油三酯血症、与甘油三酯过高相关的心血管风险，以及超重患者、糖尿病患者或其他糖代谢紊乱（如 X 综合征和/或多囊卵巢疾病）患者的胰岛素抵抗/葡萄糖不耐受。
• INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE 1(DGAT-1) AND USES THEREOF
  申请人：Metabasis Therapeutics, Inc.

  公开号：EP2408774B1

  公开（公告）日：2014-11-26
• Inhibitors of Diacylglycerol O-Acyltransferase 1 (DGAT-1) and Uses Thereof
  申请人：REDDY K. RAJA

  公开号：US20120270842A1

  公开（公告）日：2012-10-25

  The invention pertains to use of DGAT-1 inhibitors to treat and/or prevent overweight, obesity and various diseases and disorders associated therewith. Other conditions also can be ameliorated or avoided, such as high postprandial triglycerides or diet-related hypertriglyceridemia, cardiovascular risk associated with excessive triglycerides, and insulin resistance/glucose intolerance in overweight patients, those with diabetes or other glucose metabolic disorders such as Syndrome X and/or polycystic ovary disease. Compounds and compositions suitable for use in the disclosed methods are also provided.
• INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE 1 (DGAT-1) AND USES THEREOF
  申请人：METABASIS THERAPEUTICS, INC.

  公开号：US20150166590A1

  公开（公告）日：2015-06-18

  The invention pertains to the use of fused bicyclo heterocyclic adducts of thiohydroxy pyridines or pyrimidines as diacylglycerol O-acyltransferase 1 (DGAT-1) inhibitors to treat hyperlipidiemias and various diseases and disorders associated therewith. Other conditions also can be ameliorated or avoided, such as high postprandial triglycerides or diet-related hypertriglyceridemia, cardiovascular risk associated with excessive triglycerides, and insulin resistance/glucose intolerance in overweight patients, those with diabetes or other glucose metabolic disorders such as Syndrome X and/or polycystic ovary disease.